Dice Therapeutics
Pioneering oral solutions to combat chronic diseases in immunology with innovative selective small molecule therapies.
Pioneering oral solutions to combat chronic diseases in immunology with innovative selective small molecule therapies.
Dice Therapeutics is a biopharmaceutical company founded in 2013, dedicated to pioneering oral solutions for chronic diseases in the field of immunology. The company's slogan reflects its mission of developing innovative selective small molecule therapies to combat these illnesses. Their proprietary technology platform, DELSCAPE, aims to identify oral small molecules capable of modulating protein-protein interactions with the same efficacy as systemic biologics. Their leading therapeutic candidate, S011806, targets the pro-inflammatory signaling molecule interleukin-17, a recognized drug target in various immunology-related conditions. Additionally, Dice Therapeutics is working on oral therapies for inflammatory bowel disease and idiopathic pulmonary fibrosis. The company recently received a significant $345.00M Post-IPO Equity investment on 17 October 2022 to support its endeavors in revolutionizing treatment options for chronic diseases.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Post-IPO Equity | $345.00M | - | 17 Oct 2022 | |
| Series C | $60.00M | 10 |
|
24 Aug 2021 |
| Series C | $80.00M | 10 |
|
08 Jan 2021 |
| Series B | $40.48M | 1 |
|
11 Jul 2018 |
| Venture Round | $4.00M | - | 18 Jun 2015 |
No recent news or press coverage available for Dice Therapeutics.
We care about your data, and we'd love to use cookies make your experience better.
